News

Pharmaniaga On Track To Deliver 12 Mln Sinovac Vaccine Doses To Govt In July

KUALA LUMPUR, June 16 — Pharmaniaga Bhd is expected to complete its contractual obligation of supplying 12 million Sinovac COVID-19 vaccine doses to the federal government by next month, sufficient to cover some 18 per cent of Malaysia’s population.

Group managing director Datuk Zulkarnain Md Eusope said the vaccine has been approved by the World Health Organisation and the recognition is a boost of confidence in the battle against the pandemic.

“We are bullish on the group’s outlook this year and we expect a better financial year 2021 performance with the continuous ramping up of the Sinovac vaccine supply.

“The China Food and Drug Administration has recently given emergency approval for the Sinovac COVID-19 vaccine to be administered to children aged three to 17 and manufacturing of two doses per vial before submitting it to the National Pharmaceutical Regulatory Agency (NPRA) for the variation process,” he said in a statement issued in conjunction with the group’s 23rd annual general meeting and extraordinary general meeting, which were conducted through live streaming, today.

Zulkarnain said Pharmaniaga would be submitting relevant documents to the NPRA for the variation process soon.

Upon obtaining approval from the agency, it would be able to ramp up its capacity from two million to four million doses a month, he added.

As part of the company’s long-term sustainability plan, Zulkarnain said the group aims to accelerate the growth of its halal vaccine manufacturing business.

“Our plan to establish the world’s first halal vaccine facility is progressing well by working closely with both the Malaysian Investment Development Authority and also the Halal Development Corp Bhd.

“The halal vaccine project has been selected as a pioneering initiative for policy and incentive development purposes,” he said.

The halal facility is targeted to start operating in 2024 while creating a new revenue stream for the group, Zulkarnain said, adding that the initiative would generate multiple positive spillover benefits, including improving the nation’s pandemic preparedness towards cultivating a sustainable vaccine supply chain.

In addition, he said it is expected to provide opportunities for upskilling local talent while increasing access to affordable vaccines for both local and international markets.

These would subsequently position Malaysia as a global vaccine manufacturer, Zulkarnain explained.

Boustead Holdings Bhd and Lembaga Tabung Angkatan Tentera hold stakes of 55.93 per cent and 11.23 per cent, respectively, in Pharmaniaga.

At lunch break, shares of the pharmaceutical company soared 7.36 per cent to RM5.54 with 5.25 million shares transacted.

Sources: BERNAMA

Adib Mohd

Recent Posts

TV Sarawak Is Leveling Up, From Kuching to the World with Spotlight 25/26

Since its debut in 2020, TV Sarawak (TVS) has been rewriting what it means to… Read More

15 hours ago

Skechers Steps Up the Game with New Basketball Collection

Skechers, The Comfort Technology Company™ and a global leader in lifestyle and performance footwear, has… Read More

15 hours ago

LexisNexis Brings AI Legal Sidekick to Malaysia with Protégé

Move over Suits, the future of law just got an AI upgrade. LexisNexis has officially… Read More

15 hours ago

BJAK Turns Insurance Renewals into Rewards with RM100,000 Mega Giveaway This 10.10

Renewing insurance and road tax is often a last-minute hassle, but BJAK, Malaysia’s largest online… Read More

20 hours ago

SHANTEA Dessert Opens First Outlet at Mid Valley, Serving Malaysian Culture Through Sweet Creations Ahead of Visit Malaysia 2026

Malaysian flavors stepped into the spotlight today as SHANTEA Dessert officially opened its first outlet… Read More

20 hours ago

Energea Powers Up Malaysia with Bold Tangerine Collection and Next-Gen Hybrid-Solid State Powerbank

Energea, the lifestyle-driven power solutions and tech accessories brand, has officially introduced two groundbreaking innovations:… Read More

21 hours ago

This website uses cookies.